Screener
Wave Life Sciences WVE INHBE Program — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development expenses: | ||||
| INHBE program | $6,870 | $3,515 | $11,706 | $6,054 |
| AATD program | 2,989 | 1,846 | 4,739 | 3,292 |
| DMD program | 3,953 | 2,681 | 8,091 | 5,719 |
| HD program | 157 | 789 | 220 | 1,956 |
| Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM | 37,324 | 34,638 | 73,977 | 67,070 |
| Total research and development expenses | 51,293 | 43,469 | 98,733 | 84,091 |
| General and administrative expenses | 24,781 | 17,989 | 46,884 | 36,346 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's INHBE program — research and development expense?
- Wave Life Sciences (WVE) reported INHBE program — research and development expense of $6.87M in Q2 2026.
- How has Wave Life Sciences's INHBE program — research and development expense changed year-over-year?
- Wave Life Sciences's INHBE program — research and development expense increased by 95.4% year-over-year, from $3.52M to $6.87M.
- What is the long-term trend for Wave Life Sciences's INHBE program — research and development expense?
- Over 2 years (2023 to 2025), Wave Life Sciences's INHBE program — research and development expense has grown at a 728.4% compound annual growth rate (CAGR), from $229K to $15.72M.
- What does INHBE program — research and development expense mean?
- This metric represents the direct costs and allocated resources dedicated to the research, preclinical development, and clinical advancement of the INHBE-targeting therapeutic program. It captures the investment intensity required to progress this specific RNA-based candidate through the drug development pipeline. Monitoring this expense helps investors assess the company's capital allocation strategy and the pace of innovation for this particular therapeutic asset.
Ask your AI about Wave Life Sciences's inhbe program — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude